Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug cocktail aims to fight tough gynecological cancers

NCT ID NCT06906341

Disease control Sponsor: Corcept Therapeutics Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jul 17, 2026 · Updated 3 times

Summary

This study tests a drug called relacorilant, taken as a pill, combined with two standard chemotherapy drugs (nab-paclitaxel and bevacizumab) in people with ovarian, fallopian tube, peritoneal, or endometrial cancers. The goal is to see if the combination can slow cancer growth or shrink tumors. About 270 participants will join this global Phase 2 trial.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
relacorilant (a drug taken by mouth) combined with nab-paclitaxel and bevacizumab (given by IV)
What this could lead to
If successful, this could provide a new treatment option for people with certain gynecological cancers that have stopped responding to standard therapies.
What could go wrong
This is an early Phase 2 trial with a small number of participants, so results may not apply to everyone. The combination may cause side effects or not work better than existing treatments.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 270 people

The number the study aims to enrol. It can still change while the study runs.

Started

Apr 2025

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Arms A and B * Histologic diagnosis of epithelial ovarian, primary peritoneal, or fallopian-tube carcinoma * Arm A Only: Platinum-resistant disease * Arm B Only: Platinum-sensitive disease who had progression while receiving treatment with a poly(ADP-ribose) polymerase (PARP) inhibitor * Life expectancy of ≥3 months * Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1 * Able to swallow and retain oral medication * 1 to 3 lines of prior systemic anticancer therapy * Adequate organ function * Negative pregnancy test for patients of childbearing potential Arm C * Stage III or IV, recurrent, or metastatic endometrial cancer * Life expectancy of ≥3 months * ECOG performance status of 0 or 1 * Able to swallow and retain oral medication * Prior treatment with a platinum agent and an approved anti-Programmed Cell Death Ligand 1 (PD\[L\]1) antibody * 1 to 2 lines of prior systemic anticancer therapy for endometrial cancer * Must consent to provide an available formalin-fixed paraffin-embedded (FFPE) tumor tissue block or recently cut sections * Adequate organ function * Negative pregnancy test for patients of childbearing potential Exclusion Criteria: Arm A and B * Arm A Only: Has progressed while receiving weekly paclitaxel or nab-paclitaxel * Prior enrollment in a clinical trial of relacorilant * Prior anticancer therapy related toxicities not resolved to grade ≤1 * Any surgery within 4 weeks prior to enrollment * Wide-field radiation to more than 25% of marrow-bearing areas * Medical conditions requiring chronic or frequent treatment with corticosteroids * Concurrent treatment with mifepristone or other glucocorticoid receptor modulators * Peripheral neuropathy from any cause \>Grade 1 * Hypertension: ≥150 mm Hg systolic or ≥100 mm Hg diastolic * Uncontrolled condition(s) which, may confound the results of the trial or interfere with the patient's safety or participation * Bowel obstruction ≤12 weeks prior to study entry * Ascites or pleural effusions requiring therapeutic paracentesis * Untreated or symptomatic central nervous system metastases * History of other malignancy within 3 years prior to enrollment * Has received a live vaccine within 30 days prior to the study start date Arm C * Has progressed while receiving weekly paclitaxel or nab-paclitaxel * Prior enrollment in a clinical trial of relacorilant * Prior anticancer therapy related toxicities not resolved to grade ≤1 * Any surgery within 4 weeks prior to enrollment * Wide-field radiation to more than 25% of marrow-bearing areas * Medical conditions requiring chronic or frequent treatment with corticosteroids * Concurrent treatment with mifepristone or other glucocorticoid receptor modulators * Peripheral neuropathy from any cause \>Grade 1 * Uncontrolled condition(s) which, may confound the results of the trial or interfere with the patient's safety or participation * Bowel obstruction ≤12 weeks prior to study entry * Ascites or pleural effusions requiring therapeutic paracentesis * History of other malignancy within 3 years prior to enrollment * Has received a live vaccine within 30 days prior to the study start date * Patients with central nervous system metastases are not eligible, unless they have completed local therapy and have discontinued the use of corticosteroids for this indication for at least 4 weeks before starting treatment in this study.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Endometrial cancer are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

endometrial cancer endometrium neoplasm fallopian tube cancer fallopian tube carcinoma fallopian tube disorder fallopian tube neoplasm female reproductive system neoplasm neoplasm Neoplasms by Site ovarian cancer ovarian carcinoma ovarian disorder peritoneal neoplasm primary peritoneal carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Endometrial cancer Fallopian tube cancer Ovarian cancer Peritoneal neoplasms

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    49 sites in 8 countries. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • 004

    RECRUITING

    Birmingham, Alabama, 35233, United States

  • 014

    RECRUITING

    San Francisco, California, 94143, United States

  • 108

    RECRUITING

    Leuven, 3000, Belgium

  • 114

    RECRUITING

    Madrid, 28034, Spain

  • 115

    RECRUITING

    Barcelona, 08035, Spain

  • 121

    RECRUITING

    Milwaukee, Wisconsin, 53226, United States

  • 122

    RECRUITING

    Milan, 20141, Italy

  • 124

    RECRUITING

    Rome, 00168, Italy

  • 127

    RECRUITING

    Pittsburgh, Pennsylvania, 15213, United States

  • 150

    RECRUITING

    Palo Alto, California, 94304, United States

  • 255

    RECRUITING

    Berlin, 10117, Germany

  • 292

    RECRUITING

    Albuquerque, New Mexico, 97102, United States

  • 293

    RECRUITING

    Torino, 10128, Italy

  • 295

    RECRUITING

    Pavia, 27100, Italy

  • 300

    RECRUITING

    Norfolk, Virginia, 23502, United States

  • 304

    RECRUITING

    Centerville, Ohio, 45459, United States

  • 306

    RECRUITING

    Lille, 59000, France

  • 307

    RECRUITING

    Nancy, 54100, France

  • 308

    RECRUITING

    Toulouse, 31059, France

  • 310

    RECRUITING

    Nice, 06100, France

  • 319

    RECRUITING

    Treviso, 31100, Italy

  • 321

    RECRUITING

    Catania, 95126, Italy

  • 323

    RECRUITING

    Plérin, 22190, France

  • 324

    RECRUITING

    Pierre-Bénite, 69495, France

  • 325

    RECRUITING

    Hasselt, 3500, Belgium

  • 326

    RECRUITING

    Charleroi, 6000, Belgium

  • 328

    RECRUITING

    Aalst, Belgium, 9300, Belgium

  • 329

    RECRUITING

    Siedlce, 08-MO, Poland

  • 330

    RECRUITING

    Valencia, 46026, Spain

  • 334

    RECRUITING

    Kansas City, Missouri, 64132, United States

  • 335

    RECRUITING

    Miami Beach, Florida, 33140, United States

  • 341

    RECRUITING

    Gdynia, 81-519, Poland

  • 349

    RECRUITING

    Badalona, 08916, Spain

  • 396

    RECRUITING

    Seoul, Gangnam-gu, 06351, South Korea

  • 397

    RECRUITING

    Gyeonggi-do, Goyang-si, 10408, South Korea

  • 398

    RECRUITING

    Seoul, Seodaemun-gu, 03722, South Korea

  • 399

    RECRUITING

    Seoul, Jongno-gu, 03080, South Korea

  • 403

    RECRUITING

    Seoul, Songpa-gu, 05505, South Korea

  • 516

    RECRUITING

    Milan, 20159, Italy

  • 517

    RECRUITING

    Eugene, Oregon, 97401, United States

  • 518

    RECRUITING

    Minneapolis, Minnesota, 55404, United States

  • 519

    RECRUITING

    Aachen, 52074, Germany

  • 520

    RECRUITING

    Kempten, 87439, Germany

  • 521

    RECRUITING

    St Louis, Missouri, 63110, United States

  • 522

    RECRUITING

    Fairfax, Virginia, 22031, United States

  • 523

    RECRUITING

    Seoul, Seocho-gu, 06591, South Korea

  • 543

    RECRUITING

    West Palm Beach, Florida, 33041, United States

  • 544

    RECRUITING

    Fort Myers, Florida, 33901, United States

  • 558

    RECRUITING

    Valencia, 46010, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.